Skip to main content

Table 8 Differences in the approach to a first line treatment of CSU in physicians who do and do not follow the guidelines

From: Management of chronic spontaneous urticaria: a worldwide perspective

Treatment

Compared groups

n

% (n) of physicians, who follow the guidelines

% (n) of physicians, who don’t follow the guidelines

X2

p

First-generation H1-antihistamines

Administer

173

15.4 (160)

14.8 (13)

0.026

0.873

No

953

84.6 (878)

85.2 (75)

Second-generation H1-antihistamines at standard dose

Administer

704

64 (664)

45.5 (40)

11.868

0.001

No

422

36 (374)

54.5 (48)

Updosed second-generation H1-antihistamines

Administer

540

47.8 (496)

50.0 (44)

0.160

0.690

No

586

52.2 (542)

50.0 (44)

H2-antihistamines (e.g. famotidine or ranitidine)

Administer

224

19.7 (204)

22.7 (20)

0.481

0.488

No

902

80.3 (834)

77.3 (68)

Ciclosporin

Administer

15

1.4 (15)

0

1.289

0.256

No

1111

98.6 (1023)

100 (88)

Omalizumab

Administer

32

3.0 (31)

1.1 (1)

1.006

0.316

No

1094

97.0 (1007)

98.9 (87)

Montelukast

Administer

150

13.2 (137)

14.8 (13)

0.174

0.676

No

976

86.8 (901)

85.2 (75)

Dapsone

Administer

7

0.6 (6)

1.1 (1)

0.409

0.522

No

1119

99.4 (1032)

98.9 (87)

Systemic corticosteroids (for less than 10 days)

Administer

215

18.7 (194)

23.9 (21)

1.406

0.236

No

911

81.3 (844)

76.1 (67)

Systemic corticosteroids (for more than 10 days in a row)

Administer

16

1.5 (16)

0

1.376

0.241

No

1110

98.5 (1022)

100 (88)

Tricyclic antidepressants (e.g. doxepin)

Administer

35

3.0 (31)

4.5 (4)

0.655

0.418

No

1091

97.0 (1007)

95.5 (84)

  1. Values marked in bold indicate a statistically significant difference (p < 0.05)